No longer trading

Acquired by Neurocrine Biosciences, Inc.

The acquisition closed on May 18, 2026 (SEC 8-K 2.01). Its last closing price was on May 15, 2026. It has left the AI-ranked universe. The score and rank below are its final ones, from May 3, 2026. Source: SEC 8-K 2.01

SLNO

SOLENO THERAPEUTICS INC SLNO

NasdaqMid CapHealthcare

Final 13F Pro quality score

Final rank #2,061 of 2,819 · as of May 3, 2026

Why it scores 38Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$94.60M

Quarter to Mar 31

Net income

$31.38M

Quarter to Mar 31

Free cash flow

$25.94M

Quarter to Mar 31

Operating margin

33.1%

Quarter to Mar 31

Top Institutional Holders

as of Q1 2026
$1.85B total
FMR LLC
$193.80M-28.4%
WELLINGTON MANAGEMENT GROUP LLP
$148.21M+33.2%
BlackRock, Inc.
$125.31M-3.3%
STATE STREET CORP
$89.75M+1.2%
Avoro Capital Advisors LLC
$77.00M-20.7%
VANGUARD CAPITAL MANAGEMENT LLC
$72.09M--
Nantahala Capital Management, LLC
$58.39M+32.7%
Polar Capital Holdings Plc
$56.88M+49.4%
Khrom Capital Management LLC
$50.60MNew
GEODE CAPITAL MANAGEMENT, LLC
$41.44M+6.4%
Woodline Partners LP
$37.23M0.0%
Deep Track Capital, LP
$36.12M+7.9%
PRICE T ROWE ASSOCIATES INC /MD/
$34.35M+1606.6%
BRAIDWELL LP
$32.12M-19.2%
READYSTATE ASSET MANAGEMENT LP
$31.88M+8.9%
FRANKLIN RESOURCES INC
$27.96M+1.4%
Vestal Point Capital, LP
$24.44MNew
Commodore Capital LP
$21.84M-45.6%
Hood River Capital Management LLC
$20.87M+0.9%
Pictet Asset Management Holding SA
$20.63M-1.3%
MILLENNIUM MANAGEMENT LLC
$20.31M-50.9%
SCHRODER INVESTMENT MANAGEMENT GROUP
$19.75M+44.2%
Catalio Capital Management, LP
$19.35M+60.4%
KINGDON CAPITAL MANAGEMENT, L.L.C.
$19.25M+43.8%
Kynam Capital Management, LP
$18.75MNew
See all 227 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

Q1 2026
EDGAR

Net Income

Q1 2026
EDGAR

EPS (Diluted)

Q1 2026
EDGAR

Operating Margin

Q1 2026
EDGAR

ROIC

Q1 2026
EDGAR

Free Cash Flow

Q1 2026
EDGAR

Debt/Equity

Q1 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/SLNO

Earnings Per Share

13fpro.ai/company/SLNO

Loading ratio trend…

About SOLENO THERAPEUTICS INC (SLNO): stock profile, AI score and financials

Acquired by Neurocrine Biosciences, Inc.: SOLENO THERAPEUTICS INC (SLNO) no longer trades and has left 13F Pro's AI-ranked universe. The acquisition closed on May 18, 2026 (SEC 8-K 2.01). Its last closing price was on May 15, 2026. It has left the AI-ranked universe. The score and rank below are its final ones, from May 3, 2026. SOLENO THERAPEUTICS INC (SLNO) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro tracks SLNO using direct SEC EDGAR data and AI-powered research tools. Based on the latest XBRL financial filings (Q1 2026), SOLENO THERAPEUTICS INC reports quarterly revenue of $94.6M, net income of $31.4M, an operating margin of 33.1%. SLNO trades on the Nasdaq exchange and files with the SEC under CIK 1484565. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SLNO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for SOLENO THERAPEUTICS INC directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1484565 →